Steven Pennock, Ph.D
Chief Scientific Officer
With more than 15 years of experience in translational medicine and drug discovery for ocular and neurodegenerative diseases, he guides the company’s research strategy, pipeline development, and collaborations in genetic and regenerative medicine.
Dr. Pennock leverages over 15 years of experience in translational medicine and drug discovery for ocular and neurodegenerative diseases. He is responsible for the company’s research strategy, pipeline development, and partnerships in genetic and regenerative medicine.
Prior to joining Vision BioSciences, Dr. Pennock held senior research and leadership positions at Johnson & Johnson, Applied Genetics Technologies Corporation, and Regeneron Pharmaceuticals, where he established gene therapy platform capabilities and led cross-functional teams advancing multiple programs from initiation through preclinical IND-enablement. He has also supported several clinical stage gene therapies for retinal disease. Dr. Pennock has authored more than 20 peer-reviewed publications in ocular biology, gene/cell therapy, and molecular signaling and is an inventor on patents granted for AAV vector design and therapeutic application.
Dr. Pennock earned his Ph.D. in Cell Biology from the University of Alberta in Canada and completed postdoctoral training at the Massachusetts Eye & Ear Infirmary of Harvard Medical School.
